Provenge immunotherapy SipuleucelnT APC8015 a multi-step immuno-stimulant therapy, uses the patients own blood cells which are removed from the body combined with a modulatory substance and
Provenge immunotherapy (Sipuleucel-T (APC8015)) a multi-step immuno-stimulant therapy, uses the patients own blood cells which are removed from the body, combined with a modulatory substance and reapplied. The prostate cancer vaccine was originally licensed to Dendreon (Seattle, USA) being originally approved in 2010 by the FDA in the USA. The rights, assets and exclusivity of all of Dendreons therapeutics (including Provenge) was bought up by Valeant Pharmaceuticals in 2015. The highly successful treatment was costed at a phenomenal $93,000 (per each 3-phase course of treatment) at FDA approval in 2010, rising to over $100,000 in 2014. The Provenge drug trials were run by Dr Simon J Hall MD, Chair of Urology at the Mount Sinai School of Medicine. Your essay:
Comment in critical fashion on the development chronology, technical difficulties experienced, novel technology, unconventional steps to achieving success and ethical dilemmas for the Provenge vaccine to move from concept to approved therapy and formal licensed product for the treatment of metastatic (castration-resistant) (mCRPC) or asymptomatic hormone-refractory prostate cancer (AHRPC), and owned by Valeant Pharmaceuticals. Formatting of the work:
Essay (the report should be 1500 words ? 5%, with scalable-penalty for falling outside the range), structured as: Title, Your name (and student number), Introduction, sectional themes and Conclusions with appropriate citations and 10-30 References for level-7 study. work will be scanned for plagiarism (copying) and collusion and penalized if shown to demonstrate this. Guidance notes:
Work on your OWN.
Tables, titles, figures and references are not counted in the word count. References should be from credible sources and not include UG teaching textbooks or non-official websites.